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Recombinant adenoviruses are being developed for gene therapy of inherited disorders such as cystic fibrosis because
they efficiently transduce recombinant genes into nondividing cells in vivo. First generation recombinant adenoviruses,
rendered defective by deletion of sequences spanning E1a and E1b, express low levels of early and late viral genes that
activate destructive cellular immune responses. Current strategies for improving recombinant adenoviruses attempt to
inactivate other essential genes through deletion and growth in new packaging cell lines or incorporation of temperature
sensitive mutations which allow propagation of the virus in available packaging cell lines at permissive temperatures. We
describe in this report a new type of recombinant adenovirus that is deleted of all viral open reading frames. This recombinant
(called DrAd), which contains only the essential cis elements (i.e., ITRs and contiguous packaging sequence), is propagated
in 293 cells in the presence of E1-deleted helper virus. Concatamers of the monomeric vector genome were passaged and
capable of transduction. The DrAd genome is packaged into virions that sediment at a lower density than the helper virus
in cesium gradients forming the basis for a purification protocol. A fully deleted recombinant adenovirus that expresses
human cystic fibrosis transmembrane conductance regulator was produced and used to transduce human airway epithelial
cells derived from a cystic fibrosis patient. Packaging and propagation of a fully deleted adenovirus is an important step
toward the development of a safer vector. Improved production and purification strategies need to be developed before
this new vector system can be evaluated in vivo. q 1996 Academic Press, Inc.
INTRODUCTION infected with adenovirus; recombinant AAV must be puri-
fied from contaminating adenovirus in the resulting prep-
The clinical utility of gene therapy is highly dependent
aration (Samulski et al., 1989).
on the development of safe and efficient methods for
Vectors based on recombinant forms of adenovirusaccomplishing gene transfer. Many of these gene deliv-
have emerged as vehicles of choice for many applica-ery vehicles or so-called ‘‘vectors’’ are based on recombi-
tions of in vivo gene therapy. This nonenveloped virus,nant forms of viruses. Most ex vivo applications of gene
which contains a well-characterized 36-kb double-therapy use recombinant retroviruses which represent
stranded DNA genome, can be purified and producedthe first and most advanced vector system. In this non-
in high quantities, has a broad tropism, and can infectlytic system, packaging cell lines have been developed
nondividing cells (Berkner, 1988). Development of adeno-that stably express all viral genes in trans (Miller, 1992).
viral vectors has been difficult using the strategy em-The retroviral vector retains only cis acting sequences
ployed for retroviruses (i.e., produce fully deleted virusesnecessary for packaging and integration which includes
in a packaging cell line that expresses all viral genes inthe long terminal repeat and packaging sequences. Ad-
trans) because of the complexity of the adenoviral ge-eno-associated virus (AAV) represent a more recent vi-
nome. In first generation constructs, the recombinant ad-rus-based system, which, like the retroviral system, has
enovirus is rendered replication defective by deleting thebeen deleted of all viral genes and retains terminal re-
important activating genes E1a and E1b and growing thepeats and packaging sequences. It has been difficult
virus in the 293-cell line of Frank Graham, which stablydeveloping a packaging cell line in this system because
expresses E1 genes in trans (Graham and Smiley, 1977;many of the AAV and adenoviral genes necessary for
Kozarsky and Wilson, 1993). It is hoped that in the ab-recombinant AAV production are toxic to cells when ex-
sence of E1 gene products the other viral genes willpressed constitutively (Carter, 1990). Recombinant AAV
remain dormant and the virus will not replicate.is produced by transfecting the vector with a plasmid
The usefulness of recombinant adenoviruses for acontaining AAV viral genes into a cell line that is also
broad range of in vivo gene therapy applications has
been demonstrated in animal models as well as in pre-
1 To whom correspondence and reprint requests should be ad- liminary clinical attempts to treat cystic fibrosis (CF) lungdressed at Room 204, Wistar Institute, Institute for Human Gene Ther-
disease (Rosenfeld et al., 1992; Engelhardt et al., 1993;apy, 3601 Spruce Street, Philadelphia, PA 19104-4268. Fax: (215) 898-
6588. Zabner et al., 1993; Crystal et al., 1994). The efficiency
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of in vivo gene therapy has been sufficient in most sys- a plasmid was constructed for the production of a DrAd
vector that expressed the human CFTR protein. The CFTRtems to achieve potential therapeutic efficacy. With few
exceptions, however, recombinant gene expression has minigene in pAdD.CBCFTR was obtained from a recom-
binant adenovirus plasmid (pAd.CBCFTR) used to gener-not been stable and substantial pathology develops at
the site of gene transfer. Both of these problems can ate previously described first and second generation
CFTR adenovirus vectors (Engelhardt et al., 1993). Ex-be explained, in part, by the development of destructive
cellular immune responses to the genetically corrected pression of CFTR was mediated by a chimeric CB ele-
ment composed of the CMV immediate early enhancercells which express low levels of viral proteins despite
the deletion of E1 (Yang et al., 1994a, 1995). Our initial and chicken b-actin promoter. Although pAdD.CBCFTR
used the same Ad5 ITR sequences as described aboveattempt to further inactivate the recombinant adenovirus
by incorporating a temperature-sensitive mutation in the for the lacZ plasmids, the Ad5 sequences terminated
with NheI sites instead of EcoRI. Therefore, release ofE2a gene resulted in less cellular immunity and pro-
longed gene expression (Yang et al., 1994b). Leakiness pAdD.CBCFTR from plasmid was accomplished by di-
gestion with N heI. The plas mid bac kbone forof the ts mutation at 377 and basal activity of viral promot-
ers such as the major late promoter may lead to residual pAdD.CBCFTR was pSL1180 (Pharmacia). All plasmids
were grown in E. coli strain DH5a (BRL) and purified byviral gene expression and suboptimal performance of the
second generation vectors. ion-exchange chromatography (Qiagen).
We describe in this report a novel approach for gener-
Production and purification of DrAd vectorsating recombinant adenovirus that has been fully deleted
of virus encoding genes. The deleted recombinant ade-
Monolayers of 293 cells grown to 80 – 90% confluency
novirus (called DrAd) retains only the inverted terminal
in 150-mm culture dishes were infected with H5.CBALP
repeat and adjacent packaging sequences and is grown
(Yang et al., 1995) at an m.o.i. of 5. Infections were done
in 293 cells in the presence of E1-deleted helper virus.
in Dulbecco’s Modified Eagle Media (DMEM) supple-
The DrAd virus can be separated from the bulk of the
mented with 2% fetal bovine serum (FBS) at 20 ml media/
helper virus by sedimentation through cesium gradients.
150-mm plate. Two hours postinfection, 50 mg plasmid
A version of the DrAd virus that contains a human CF
DNA (EcoRI-restricted pAdD.CMVlacZ, pAdDc.CMVlacZ,
transmembrane conductance regulator (CFTR) minigene
or NheI-restricted pAdD.CBCFTR) in 2.5 ml of transfec-
was generated and used to transduce human airway tion cocktail was added to each plate and evenly distrib-
primary epithelial cells from a patient with CF. uted. Transfections were calcium-phosphate based as
described (Cullen, 1987). Cells were left in this condition
MATERIALS AND METHODS
for 10– 14 hr, after which the infection/transfection media
was replaced with 20 ml fresh DMEM/2% FBS. Approxi-Plasmids
mately 30 hr posttransfection, cells were harvested, sus-
Two plasmids were engineered for the production of
pended in 10 mM Tris – Cl (pH 8.0) buffer (0.5 ml/150-mm
DrAd vectors that express Escherichia coli b-galactosi-
plate), and stored at 0807.
dase. The first of these, pAdD.CMVlacZ (Fig. 1), was
Frozen cell suspensions were lysed by three sequen-
based on a restriction-dependent strategy where diges-
tial rounds of freeze (ethanol-dry ice)-thaw (377). Cell de-
tion with EcoRI would release the terminal ends of the
bris was removed by centrifugation (5,000 g for 10 min)
AdD.CMVlacZ genome from the plasmid backbone. The
and 10 ml clarified extract was layered onto a CsCl step
relevant components of the DrAd vector genome in- gradient composed of three 9.0-ml tiers with densities of
cluded sequence from the left-end of Ad5 encompassing 1.45, 1.36, and 1.20 g/ml CsCl in 10 mM Tris – Cl (pH 8.0)
bp 1– 360 (5* inverted terminal repeat (ITR)), a lacZ mini- buffer. Centrifugation was performed at 20,000 rpm in a
gene under the transcriptional control of the cytomegalo-
Beckman SW-28 rotor for 8 hr at 47. Fractions (1.0 ml)
virus (CMV) immediate early enhancer/promoter, and se-
were collected from the bottom of the centrifuge tube
quence from the right-end of Ad5 spanning bp 35,353 to
and analyzed for DrAd transducing vectors. Peak frac-
the end of the genome (3* ITR). The second lacZ plasmid
tions were combined and banded to equilibrium. Frac-
constructed, pAdDc.CMVlacZ, was designed to enable
tions containing transducing virions were dialyzed
restriction-independent production of lacZ DrAd vectors
against 20 mM HEPES (pH 7.8)/150 mM NaCl (HBS) and
(Fig. 1). This plasmid was identical to pAdD.CMVlacZ in
stored frozen at 0807 in the presence of 10% glycerol or
composition; however, the 3* ITR domain was moved to
as a liquid stock at 0207 (HBS / 40% glycerol).
a position immediately adjacent to the 5* ITR sequence.
This resulted in a head-to-tail orientation of the 5* and Functional analysis of DrAd vectors
3* terminal domains, respectively. The plasmid backbone
for pAdD.CMVlacZ and pAdDc.CMVlacZ was pSP72 Fractions collected after ultracentrifugation were ana-
lyzed for transgene expression and vector DNA. For lacZ(Promega).
Following the restriction-dependent approach (Fig. 1), DrAd vectors, 2-ml aliquots were added to 293 cell mono-
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FIG. 1. Strategy for production of DrAd vectors. (A) The two plasmids that were constructed for the production of DrAd vectors that express E.
coli b-galactosidase are shown (see Materials and Methods for details). Plasmid pAdD.CMVlacZ (restriction-dependent) was engineered with EcoRI
sites flanking the 5* and 3* Ad5 ITR sequences. Therefore, digestion with EcoRI would free the DCMVlacZ genome from the plasmid shuttle vector
and facilitate recognition of the ITRs by nuclear replicons. Plasmid pAdDc.CMVlacZ (restriction-independent) was designed to alleviate the need
for enzyme restriction by placing the 5* and 3* ITRs in a head-to-tail configuration. The elements that are labeled include sequence from the left
(5* ITR) and right ends (3* ITR) of Ad5, the cytomegalovirus immediate early promoter/enhancer (CMV), splice site donor-acceptor sequence from
SV40 (SD/SA), b-galactosidase cDNA from E. coli (lacZ), and polyadenylation signal from SV40 (pA). (B) Production of DrAd vectors involved two
steps. First, 293 cells seeded in 150-mm dishes were infected with helper virus H5.CBALP at an m.o.i. of 5. This step was necessary to provide in
trans the necessary helper functions for synthesis and packaging of DCMVlacZ genomes. Two hours later cells were transfected with either EcoRI-
restricted pAdD.CMVlacZ or pAdDc.CMVlacZ, thereby providing a cis replication template. (C) Ultracentrifugation through CsCl gradients was used
to separate H5D.CMVlacZ vectors from helper virus H5.CBALP. Purification of lacZ DrAd vectors could be easily monitored by reporter gene
expression; alkaline phosphatase staining marked H5.CBALP helper virus while lacZ staining indicated DrAd vector transduction.
layers seeded in 35-mm culture wells. Twenty-four hours vector was determined by immunofluorescence localiza-
tion. Aliquots of H5D.CBCFTR, enriched by two rounds oflater cells were harvested, suspended in 0.3 ml 10 mM
Tris– Cl (pH 8.0) buffer, and lysed by three rounds of ultracentrifugation and exchanged to HBS storage buffer,
were added to primary cultures of airway epithelial cellsfreeze-thaw. Cell debris was removed by centrifugation
(15,000 g for 10 min) and assayed for total protein (Brad- obtained from the lungs of CF transplant recipients.
Twenty-four hours after the addition of vector, cells wereford, 1976) and b-galactosidase activity (Sambrook et
al., 1989) using o-nitrophenyl b-D-galactopyranoside as harvested and affixed to glass slides using centrifugal
force (Cytospin 3, Shandon Scientific Limited). Cells weresubstrate.
Expression of CFTR protein from the H5D.CBCFTR fixed with freshly prepared 3% paraformaldehyde in PBS
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(1.4 mM KH2PO4, 4.3 mM Na2HPO4, 2.7 mM KCl, and 137
mM NaCl) for 15 min at room temperature (RT), washed
twice in PBS, and permeabilized with 0.05% NP-40 for 10
min at RT. The immunofluorescence procedure began
with a blocking step in 10% goat serum (PBS/GS) for 1
hr at RT, followed by binding of the primary monoclonal
mouse anti-human CFTR (R-domain-specific) antibody
(Genzyme) diluted 1:500 in PBS/GS for 2 hr at RT. Cells
were washed extensively in PBS/GS and incubated for
1 hr at RT with a donkey anti-mouse IgG (H / L) FITC-
conjugated antibody (Jackson ImmunoResearch Labora-
tories) diluted 1:100 in PBS/GS.
FIG. 2. Fractionation of H5D.CMVlacZ through a discontinuous CsClStructural analysis of DrAd vectors gradient. An extract (10 ml) from 293 cells that were infected with
H5.CBALP and transfected with EcoRI-restricted pAdD.CMVlacZ wasFor Southern analysis of vector DNA, 5-ml aliquots
layered onto a discontinuous gradient as described under Materials
were taken directly from CsCl fractions and incubated and Methods. Centrifugation for 8 hr at 72,128 g resulted in separation
with 20 ml capsid digestion buffer (50 mM Tris – Cl, pH of infectious H5.CBALP (Ad) from incompletely formed virions (TC) as
shown in the cartoon. Fractions were collected from the interfacing8.0; 1.0 mM EDTA, pH 8.0; 0.5% SDS, and 1.0 mg/ml
zone between Ad and TC and analyzed by Southern blot hybridizationProteinase K) at 507 for 1 hr. The reactions were allowed
(left of tube) or for the presence of lacZ transducing particles (right ofto cool to RT, loading dye was added, and electropho-
tube). The autoradiogram positioned to the left of the tube and on its
resed through a 1.2% agarose gel. DNA was also purified side shows the Southern blot results. The top of the gel is labeled (0)
by phenol extraction and restricted with ClaI before DNA and the bottom (/). Numbers indicate lane positions loaded with the
respective fraction. Bands corresponding to helper virus H5.CBALP andhybridization analysis. Resolved DNAs were electroblot-
DrAd vector H5D.CMVlacZ are located with an arrow. For functionalted onto a nylon membrane (Hybond-N) and hybridized
analysis, aliquots from the same fractions were added to monolayerswith a 32P-labeled restriction fragment. Blots were ana-
of 293 cells and the expression of recombinant b-galactosidase was
lyzed by autoradiography or scanned on a Phosphor- determined 24 hr later. The specific activity (milliunits b-galactosidase/
Imager 445 SI (Molecular Dynamics). mg protein) of reporter enzyme measured from indicator cells is listed
to the right of the tube.
Sequence analysis of propagated virions
Virions that were propagated through two rounds of Applied Biosystems Model 373 fluorescent DNA se-
amplification and concentrated by buoyant density ultra- quencer.
centrifugation in CsCl were digested with Proteinase K
(1 mg/ml) in 50 mM Tris – Cl (pH 8.0) buffer containing RESULTS
0.5% SDS and 2 mM EDTA (pH 8.0). After a 2-hr incuba-
Production of a fully deleted recombinant adenovirustion at 507, the reaction was extracted twice with an equal
was accomplished in three steps: (1) a plasmid basedvolume of phenol:chloroform:isoamylalcohol (50:48:2)
vector was constructed that contains the deleted recom-and ethanol precipitated. Viral DNA was suspended in
binant adenovirus genome, (2) recombinant viruses thatbuffer containing 10 mM Tris– Cl (pH 8.0), 1.0 mM EDTA.
package the deleted recombinant genome (i.e., theTwo oligonucleotides were synthesized that aligned to
DrAd) were produced by transfecting the plasmid intosequence in the 3* untranslated region of the lacZ cDNA
cells infected with helper virus, and (3) the DrAd virus(Primer 1 bp 4539– 4558; 5*-GATTTGGCTACATGA-
was separated from the helper virus using sedimentationCATCA-3* ) or the CMV promoter (bp 6182– 6163; 5*-CAT-
techniques.GGTAATAGCGATG-3* ). This combination of primers
when used in a PCR reaction would amplify a segment
Construction of a deleted recombinant adenoviral
of DNA 1643 bp in length if the dimer arrangement was
genome
tandem (head-to-tail). The primers were also used inde-
pendently to identify tail-to-tail (Primer 1; 1913-bp prod- The minimal components of the adenoviral genome
necessary for efficient packaging and transduction haveuct) and head-to-head (Primer 2; 1373-bp product) ar-
rangements. PCR reactions were performed with 10 ng yet to be determined. We reasoned that an absolute re-
quirement would be the ITR sequences in addition to theviral DNA using a cycling program of 947 (1 min), 527 (1
min), and 727 (1 min 30 sec). A total of 30 cycles were five repetitive sequences contiguous to the 5* ITR which
are believed to be involved in packaging (Gra¨ble andperformed. PCR products were analyzed by agarose
electrophoresis and subcloned directly into plasmid Hearing, 1992). Figure 1A depicts the structure of two
versions of the plasmids used to produce DrAd virus.pCRII (Invitrogen) for sequence and restriction analysis.
DNA sequencing of PCR products was performed on an The plasmid pAdD.CMVlacZ contains a lacZ minigene
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cloned between the 5* ITR/packaging sequence and 3*
ITR of human Ad5; this recombinant genome was cloned
into the EcoRI site of the bacterial plasmid pSP72. The
second recombinant plasmid, pAdDc.CMVlacZ, juxta-
poses the 5* ITR/packaging sequence and 3* ITR in a
plasmid, placing the b-lactamase gene and bacterial ori-
gin of replication internal to the viral ITRs.
Production of recombinant adenoviruses containing
the deleted genomes
The schema for production of deleted recombinant ad-
enoviral genomes is summarized in Figs. 1 A– C. The
DrAd plasmid is transfected into 293 cells which are
subsequently infected with E1 deleted adenovirus to pro-
vide functions in trans necessary to package virus. The
resulting lysate should contain a mixture of DrAd virus
and helper virus. To help in discriminating these two
populations of virus we incorporated the lacZ gene into
the DrAd genome and the alkaline phosphatase (ALP)
reporter in place of the E1 gene of the helper virus. The
resulting lysate was used to infect target cells that were
analyzed for transduction of lacZ and ALP by histochemi-
cal staining.
The initial attempt to produce DrAd virus by transfec-
tion of the intact pAdD.CMVlacZ plasmid into 293 cells
followed by infection with helper virus was unsuccessful.
One explanation is that neither ITR was exposed so that
ligation of terminal protein and DNA replication was not
possible. Experiments were repeated with the
pAdD.CMVlacZ plasmid after the DrAd genome was re-
leased by digestion with EcoRI. Infection of 293 cells
with the resulting lysate demonstrated both lacZ and ALP
transducing virions at a ratio of approximately 1 to 104.
Graham and colleagues have developed a strategy for
generating E1- or E3-deleted recombinants using a plas-
mid that contains the 3* and 5* ITRs ligated head to tail;
this configuration allowed rescue of the plasmid-based
Ad genome for recombination and packaging (Graham,
1984). A similar strategy was developed in the DrAd
system with the potential advantage that the plasmid
DNA used in the transfection does not have to be re-
stricted. Use of undigested pAdDc.CMVlacZ in the pro-
duction schema presented in Fig. 1A yielded lacZ trans-
H5.CBALP helper virus. Fractional analysis for transducing virions was
performed on indicator 293 cells with an expression time of 24 hr. For
each panel that is shown, fraction numbers are given along the horizontal
axis. Comparative variables are assigned to the vertical axis. (A) The
absorbance at 260 nm is plotted against density calculated from refractive
index. (B) The absorbance at 260 nm is plotted against b-galactosidase
specific activity (milliunits b-galactosidase/mg protein) measured from
indicator cells. The lacZ profile here corresponds to the banding profileFIG. 3. Properties of H5D.CMVlacZ banded to equilibrium in CsCl.
of H5D.CMVlacZ vector. (C) The absorbance at 260 nm is plotted againstPeak fractions of H5D.CMVlacZ from a discontinuous gradient were
alkaline phosphatase-specific activity (milliunits alkaline phosphatase/mgcombined and banded to equilibrium in a Beckman NVT-90 rotor. Frac-
protein) measured from indicator cells. The ALP profile here correspondstions were harvested from the bottom of the tube and measured for
to the banding profile of H5.CBALP virions.absorbance at 260 nm, refractive index, H5D.CMVlacZ vector, and
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inating the contaminating helper in the final preparation
of recombinant virus. We reasoned that substantial differ-
ences in the size and composition of the recombinant
and helper genomes may impact on the configuration of
the resulting viruses sufficient to allow for fractionation
and eventual purification of theDrAd virus. A lysate from
a production run was fractionated through a discontinu-
ous cesium gradient and fractions were analyzed for (1)
viral DNA using a probe common to both the DrAd virus
and helper virus, and (2) transducing lacZ virus by analyz-
ing lysates of infected 293 cells for b-galactosidase activ-
ity. Figure 2 presents a schematic of the resulting cesium
gradient marking the location of the helper virus band
(labeled Ad) and the incompletely formed adenovirus par-
ticles referred to as top components (labeled TC). lacZ
transducing activity migrated at a peak between and
clearly distinct from the helper Ad and TC bands resulting
in an approximate 100-fold separation of DrAd virus from
helper virus. Southern analysis of this area of the gradient
revealed a band that comigrates with the EcoRI-re-
stricted pAdD.CMVlacZ genome as well as higher mo-
lecular weight bands that migrated at lower densities
than the helper genome.
Fractions with b-galactosidase activity from the dis-
continuous gradient were sedimented through an equi-
librium cesium gradient to further enrich the preparationFIG. 4. Southern blot analysis of partially purified H5D.CMVlacZ.
Aliquots from fractions 8 –17 described in the legend of Fig. 3 were for DrAd virus. The biochemical properties of this gradi-
treated with capsid digestion buffer and the released DNA was evalu- ent are summarized in Fig. 3, including density (Fig. 3A),
ated by blot hybridization. At the bottom of the figure is a cartoon of
lacZ transducing activity (Fig. 3B), ALP transducing activ-the centrifuge tube (shown on its side) from which the fractions were
ity (Fig. 3C), and absorbance at 260 nm (Figs. 3A– 3C).collected. The location of infectious H5.CBALP helper virus (Ad) and
A linear gradient was generated in the area of the DrAdincompletely formed virions (TC) are labeled with an arrow. The position
of each fraction relative to these two markers is also indicated. In the virus spanning densities 1.29 to 1.34 g/ml. A sharp peak
lower panel (labeled lacZ), the blot was hybridized with a lacZ-specific ofDrAd virus, detected as the appearance of b-galactos-
probe to detect H5D.CMVlacZ DNA. The top (0) and bottom (/) of the
idase activity in infected 293 cells, eluted between 1.31blot are labeled. Fraction numbers are given along the top of the gel
and 1.33 g/ml. This peak of DrAd virus was located be-as is the location of a marker (M) lane containing a sample of EcoRI
tween two major A260 nm absorbing peaks and in an arearestricted pAdD.CMVlacZ. Therefore, the band that appears in this lane
is equivalent to a monomer form (Form I, 5.5 kb) of the H5DCMVlacZ of the gradient where the ALP virus was precipitously
genome. Two additional species of the H5DCMVlacZ genome that dropping off. The equilibrium sedimentation gradient ac-
were identified with the lacZ-specific probe are indicated. The approxi-
complished another 102- to 103-fold purification of DrAdmate size of these two alternative forms, Form II and Form III, extrapo-
virus from helper virus. The yield of DrAd lacZ virus re-lated from a HindIII-digested lambda DNA ladder was 10 and 15 kb,
covered from a 50-plate preparation after two sedimenta-respectively. The blot was stripped and reprobed with an ALP-specific
probe to detect H5.CBALP helper virus DNA, and the results are shown tions ranged from 106 to 107 transducing particles.
in the upper panel (labeled ALP). The band corresponding to the full- A more detailed molecular characterization of the re-
length 35 kb H5.CBALP genome is indicated. sulting preparation of DrAd virus was performed by sub-
jecting aliquots of the fractions to Southern analysis us-
ducting virions at levels consistently lower than that ing probes specific to either the recombinant virus (Fig.
achieved with EcoRI restricted pAdD.CMVlacZ plasmid 4, bottom panel) or helper virus (Fig. 4, top panel). The
(data not shown). Unless otherwise noted, all subsequent most striking finding was the existence of forms of re-
experiments were performed in 293 cells with EcoRI- combinant virus with distinct genome sizes: form I corre-
restricted pAdD.CMVlacZ plasmid and the E1-deleted sponds to a genome whose size is identical to the dou-
ALP expressing helper virus. ble-stranded H5D.CMVlacZ genome, form II is a minor
band whose size is approximately twice that of the mono-
Separation of deleted recombinant virus from helper
mer and whose peak is displaced one fraction to the
virus
bottom of the gradient, and form III is a much larger
and more predominant band whose peak is even furtherAn important limitation of using helper virus in the
production of recombinant viruses is the difficulty in elim- displaced toward a more dense area of the gradient.
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The abundance of each form of the viral genome was
quantitated and directly correlated with lacZ transducing
activity in Fig. 5. The appearance of form III most consis-
tently corresponds with lacZ transducing activity.
The Southern blot hybridized with the recombinant-
specific probe was stripped and rehybridized with a
helper virus-specific probe in Fig. 4, top panel. Virus with
intact helper genomes was detected in all fractions with
the largest quantities found toward the bottom of the
gradient. A heterogeneous population of viruses with
smaller helper genomes were also detected in a region
of the gradient where forms I – III of the DrAd virus were
found.
Passage and amplification of DrAd virus
Essential to the success of this system for gene ther-
apy is the ability to passage and amplify virus containing
the recombinant genome. A lysate was prepared from
ten 150-mm plates of 293 cells transfected with pAdD.C-
MVlacZ and infected with H5.CBALP adenovirus. Analy-
sis of individual fractions from a purified lysate revealed
recovery of 3 1 106 lacZ transducing particles (Fig. 6A)
and 3.5 1 109 ALP transducing particles (Fig. 6B). Frac-
tions with the highest ratio of lacZ/ALP transducing activ-
ity (3 and 4) were used to infect five 150-mm plates and
further passaged to ten 150-mm plates of 293. The re-
sulting lysates were fractionated on cesium gradients
and individual fractions analyzed for lacZ (Fig. 6A) and
ALP (Fig. 6B) transduction. lacZ virus amplified 21-fold
from fraction 3 and threefold from fraction 4, whereas
both fractions realized a 50-fold expansion of helper vi-
rus. A similar amplification of DrAd virus has been dem-
onstrated with wild-type Ad as the helper (data not
shown).
DrAd forms transduction competent concatamers
DNA hybridization analysis of DrAd virus fractionated
from the first lysate indicated a direct correlation be-
tween lacZ transduction and the highest molecular
weight species (Form III, see Fig. 4). More detailed mo-
lecular analyses were performed to characterize the
structure of the larger DrAd genomes.
One model, suggested by the unit increment in molecu-
lar weight of Forms I, II, III, is that the larger species are
concatamers of the transfected DrAd monomer. DNA hy-
bridization analysis of the initial and amplified preparations
of lacZ DrAd virus was performed to evaluate this model.
(milliunits b-galactosidase/mg protein) measured from indicator cells
FIG. 5. Gradient profile of lacZ vector transduction in relation to the and counts-per-minute (CPM) are plotted along the vertical axis. (A)
different molecular forms of H5D.CMVlacZ. The three molecular forms lacZ vector transduction profile aligned with Form I quantitation profile.
(I, II, and III) of H5D.CMVlacZ (see Fig. 4) were quantitated and plotted (B) lacZ vector transduction profile aligned with Form II quantitation
against the lacZ transduction profile (see Fig. 3B). In each panel, the profile. (C) lacZ vector transduction profile aligned with Form III quanti-
fraction number is given along the horizontal axis. Specific activity tation profile.
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FIG. 6. Propagation and amplification of H5D.CMVlacZ. Cell lysates from 293 cells that were infected with H5.CBALP and transfected with EcoRI-
restricted pAdD.CMVlacZ were harvested and partially purified with two rounds of CsCl gradient centrifugation. Fractions (100 ml) were collected
from the bottom (lower number) to the top (higher number) of the gradient. Fractions were analysed for lacZ transduction on 293 cells by histochemical
staining. Contaminating helper virus H5.CBALP was quantitated by alkaline phosphatase histochemical staining. Portions of original fractions 3 and
4 (70 ml) were used to passage and amplify H5D.CMVlacZ from 5 to 10 plates of 293 cells. Cell lysates were harvested and purified as previously
described. Original fractions before propagation are shown here as open circles. Fractions from the original purification were shown as open
circles. Amplified fractions from 3 and 4 are shown as solid circles and open triangles, respectively.
The strategy employed to identify and discriminate different recombination with the helper genome. Figure 7B presents
DNA hybridization analysis of DrAd fractions isolated fol-DrAd concatamers is summarized in Fig. 7A. Restriction
with ClaI, an endonuclease with a single site within DrAd lowing the initial transfection (lanes 3– 8) and subsequent
amplification (lanes 9–13).genome, and hybridization of the resulting filter with a lacZ
probe, yields restriction patterns unique to head-to-tail, Restriction fragments released with ClaI suggested the
presence of a mixture of different concatamers that arehead-to-head, and tail-to-tail concatamers. Furthermore,
the helper virus has no ClaI sites so any restriction of the not solely caused by recombination with helper viral ge-
nomes. Fragments of 2.1 and 3.3 kb in length were de-higher molecular DrAd genomes cannot be explained by
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FIG. 7. Analysis of the structure of H5D.CMVlacZ virus. (A) ClaI restriction sites in H5D.CMVlacZ. Dimers in head-to-tail, head-to-head, and tail-
to-tail configurations are shown. Fragments which hybridize to the lacZ probe are indicated. Hatched boxes, 5* and 3* ITR; Arrowhead, CMV
promoter; black line, lacZ gene; j, junction between ITRs. (B) Viral DNA was extracted from original and passaged fractions, each digested with
ClaI, electrophoresed, transferred to a filter, and probed with lacZ. Lanes: 1, E1 deleted H5.CMVlacZ viral DNA, 36 kb; 2 and 14, linearized pAdD
CMVlacZ, 5.5 kb; 3 – 8, original CsCl fractions digested with ClaI; and 9 –13, fractions from repeated passages digested with ClaI.
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FIG. 8. Sequence and structure of the junction that joins two monomer length H5D.CMVLacZ genomes. The structure of two H5D.CMVlacZ
genomes arranged in a tandem array is shown in A. A magnified view of the junction is shown in B. The relevant coding (LacZ), regulatory (CMV
promoter and SV40 polyadenylation signal), and adenovirus terminal sequences (5* ITR and 3* ITR) are indicated. The junction (black circle with
lower case ‘‘j’’) is also labeled. Bold arrowheads mark the location of PCR primers that were used for amplification of junctional sequence. Arrows
below the diagram in B show the direction and extent of sequence analysis. In C, the predicted junctional sequence assuming a direct end-to-end
union of the 3* ITR and 5* ITR is shown above the actual sequence as determined by DNA sequencing of the PCR product. The jointed arrows
between the two sequences mark the divergence. The underlined CG in the actual sequence locates the apex of a potential hairpin.
tected representing the 5* and 3* termini of the DrAd Genetic correction of the defect in CF airway
epithelial cells with DrAd virus containing a humangenome. Discrete higher molecular weight fragments
consistent with internal fragments of concatamers were CFTR minigene
detected in virus from the initial transfection/infection
A plasmid was constructed in which the CMVlacZ mini-
and were clearly increased relative to the terminal frag-
gene of H5D.CMVlacZ was replaced with a CMV-en-
ments in the amplified fractions. The most intense bands
hanced b-actin promoter-human CFTR cDNA and used
comigrated with the internal fragment of a head-to-tail
to generate the corresponding DrAd virus. The resulting
concatamer (i.e., 5.3– 5.6 kb). A band comigrating with
lysate was fractionated on sequential CsCl gradients and
the head-to-head internal fragment (i.e., 6.5 kb) was
fractions containing CFTR sequences, migrating be-
also well represented with far less DNA migrating with
tween the Ad and TC peaks, were used to infect primary
the fragment of a tail-to-tail concatamer.
cultures of human airway epithelial cells derived from aA more detailed structural analysis of the junctions
CF patient. The cultures were subsequently analyzed for
within the concatamers was conducted. Figure 8 summa-
expression of CFTR protein by immunocytochemistry
rizes the strategy used in this analysis as well as the
(Fig. 9). Analysis of mock-infected CF cells failed to reveal
results. Oligonucleotides upstream of the 5* ITR (i.e., in
significant binding to the human R domain specific CFTR
the CMV promoter) and 3* ITR (i.e., in the SV40-poly(A))
antibody (Fig. 9A). Primary airway epithelial cultures ex-
were used to amplify junction fragments. The only detect-
posed to the DrAd CFTR virus demonstrated high levels
able product of amplification was a 1643-bp band ob-
of CFTR protein in 10– 20% of the cells.
tained in reactions containing both the 5* and 3* oligonu-
cleotides consistent with the existence of head-to-tail
DISCUSSION
concatamers. Sequence analysis of this band confirmed
the presence of a head-to-tail concatamer in which 20 First generation recombinant adenoviruses may have
limited utility in gene therapy of chronic disorders be-nucleotides of terminal ITR sequence was deleted and
replaced with a GC dinucleotide. The resulting contigu- cause the deletion of E1a and E1b is insufficient to render
the virus completely replication deficient. In second gen-ous sequence forms an extended inverted repeat.
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nomes of approximately normal length whose structure
includes approximately 1 kb of 5* Ad12 sequence fused
with a large fragment of cellular genomic repetitive se-
quences. SYREC virus is separated by cesium gradient
sedimentation from the associated Ad 12 virus which is
required to passage the variant virus. SYREC variants
have also been detected in stocks of Ad5 (Gluzman and
Sambrook, 1980). The presence of 5* viral sequence in all
SYREC isolates suggests the presence of cis elements in
this region of the virus that are necessary for replication
and packaging. This is consistent with a model of adeno-
viral replication in which the origin resides in the ITR
sequence and the required cis acting packaging se-
quences, so called ‘‘A repeats,’’ located in a 150-nt region
contiguous with the 5* ITR (Gra¨ble and Hearing, 1992).
Our strategy for production of a fully deleted virus is
to incorporate the minimal cis elements necessary for
packaging into a D vector and to provide the required
trans products (i.e., viral proteins necessary for formation
of virions) with a helper virus. We reasoned that the mini-
mal cis elements required for theD vector would include
both ITRs and the 5* packaging sequence. Analysis of
lysates of cells transfected with the DrAd vector and
infected with helper revealed virions capable of transduc-
ing the recombinant minigene contained within the vec-
tor. The recombinant genome can be serially passaged
and amplified.
Molecular analysis of partially purified DrAd virus
demonstrated packaging of multiple molecular forms of
vector-derived sequence. The predominant form of theD
viral genome was the size of the corresponding double-
stranded DNA monomer with less abundant but discrete
FIG. 9. Efficient targeting of human airway epithelial cells with a
higher molecular weight species also present. Impor-DrAd vector that expresses CFTR (H5D.CBCFTR). (A) H5D.CBCFTR
tantly, the peak of vector transduction activity corre-vector was added to primary cultures of human airway epithelial cells
from the lungs of a CF transplant recipient. Immunofluorescent detec- sponds with the highest molecular weight form of the D
tion with mouse anti-human CFTR (R domain specific) antibody was virus. An apparently ordered or preferred rearrangement
done 24 hr after the addition of vector. (B) Immunofluorescent detection of the DrAd monomer genome leads to a more biologi-
of a mock-transduced culture of CF airway epithelial cells.
cally active form of the virus. The fact that the larger
molecular species of the DrAd genome, i.e., forms II and
III, are 21- and 31-fold larger than the monomer DrAderation viruses, inactivation of other essential genes
such as those contained within E2 and E4 may render genome (Form I) suggests that the rearrangements may
involve sequential duplication of the original genome.the virus less likely to express viral genes and replicate.
Reversion of these mutations and virus independent acti- Detailed structural analyses of the amplified and en-
riched fractions confirmed the presence of different typesvation of the major late promoter, however, may limit the
performance of second generation viruses. The goal of of concatamers. The formation of repeated DrAd ge-
nomes in this system is also consistent with the experi-this study is to develop a truly defective adenovirus-
based vector system in which a recombinant adenoviral ence in SYREC viruses in which the bulk of the viral
genome contains repetitive cellular sequences (Deuringgenome void of viral open reading frames is packaged
into a functional virion. et al., 1981). A recent report from Matini et al. used helper
virus to expand a recombinant adenovirus that was de-The feasibility of isolating recombinant adenoviruses
substantially deleted of viral sequences was suggested leted of both E1 and a 7.3-kb segment spanning L1, L2,
VAI, and pTP (Mitani et al., 1995). Their recombinant vec-in studies performed in the 1970’s of replication compe-
tent Ad12 virus (Burlingham et al., 1974). Variants of Ad12, tors, which were substantially larger than the ones used
in this study, also underwent a consistent recombinationcalled SYREC viruses (i.e., symmetric virus), frequently
emerge after serial passage of the wild-type virus (Deur- event that resulted in the deletion of sequences.
Critical to the eventual application of D viruses foring et al., 1981). These variants contain rearranged ge-
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A. R. Kimmel, Eds.), Vol. 152, pp. 684–704. Academic Press, Sangene therapy will be the ability to separate viruses with
Diego.the recombinant genome from the helper viruses. The
Daniell, E. (1976). Genome Structure of Incomplete Particles of Adenovi-
experience with SYREC viruses suggested that this may rus. J. Virol. 19, 685– 708.
be accomplished by sedimentation through cesium gra- Deuring, R., Klotz, G., and Doerfler, W. (1981). An unusual symmetric
recombinant between adenovirus type 12 DNA and human cell DNA.dients (Burlingham et al., 1974; Deuring et al., 1981). Vi-
Proc. Natl. Acad. Sci. USA 78, 3142– 3146.ruses containing any one of the three molecular forms
Engelhardt, J. F., Yang, Y., Stratford-Perricaudet, L. D., Allen, E. D.,of DrAd viral genome are clearly distinguished from the
Kozarsky, K., Perricaudet, M., Yankaskas, J. R., and Wilson, J. M.
peak band of helper virus. We have found, however, that (1993). Direct Gene Transfer of Human CFTR Into Human Bronchial
little additional purification is achieved if the preparations Epithelia of Xenografts with E1 Deleted Adenoviruses. Nat. Genet.
4, 27 – 34.are subjected to sequential sedimentation through ce-
Gluzman, Y., and Sambrook, J. (1980). In ‘‘DNA Tumor Viruses’’ (J. Tooze,sium gradients. This is caused, in part, by packaging of
Ed.), pp. 609–610. Cold Spring Harbor Laboratory, Cold Spring Har-shorter forms of the helper genome that comigrate with bor, NY.
viruses containing the larger DrAd viral genomes. Incor- Gra¨ble, M., and Hearing, P. (1992). cis and trans Requirements for the
poration of smaller rearranged forms of adenoviruses Selective Packaging of Adenovirus Type 5 DNA. J. Virol. 66, 723–
731.into infectious virions has been described in a variety of
Graham, F. L. (1984). Covalently closed circles of human adenovirushuman serotypes (Daniell, 1976).
DNA are infectious. EMBO J. 3, 2917– 2922.
This study describes an approach for isolating recom- Graham, F. L., and Smiley, J. (1977). Characteristics of a Human Cell
binant forms of Ad5 that are fully deleted of viral open Line Transformed by DNA from Human Adenovirus Type 5. J. Gen.
Virol. 36, 59 –74.reading frames. Sedimentation through cesium affects a
Kozarsky, K. F., and Wilson, J. M. (1993). Gene Therapy: Adenoviruspartial separation of DrAd virus from helper virus. For
vectors. Curr. Opin. Genet. Dev. 3, 499– 503.this to be useful for gene therapy, better purification
Miller, A. D. (1992). Retroviral Vectors. Curr. Topics Microbiol. Immunol.
schemes are necessary and production will have to be 158, 1– 24.
increased by several orders of magnitude. Mitani, K., Graham, F. L., Caskey, C. T., and Kochanek, S. (1995). Rescue,
propagation, and partial purification of a helper virus-dependent ade-
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